Equities

ZIM Laboratories Ltd

ZIMLAB:NSI

ZIM Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)111.40
  • Today's Change0.72 / 0.65%
  • Shares traded95.05k
  • 1 Year change-6.39%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:02 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments10264116
Total Receivables, Net1,035989898
Total Inventory832621833
Prepaid expenses18189.81
Other current assets, total290218265
Total current assets2,2761,9092,121
Property, plant & equipment, net1,8041,2161,069
Goodwill, net1.691.691.69
Intangibles, net225139103
Long term investments0.520.520.52
Note receivable - long term13512797
Other long term assets221721
Total assets4,4683,4163,416
LIABILITIES
Accounts payable624582811
Accrued expenses505730
Notes payable/short-term debt550229173
Current portion long-term debt/capital leases180135163
Other current liabilities, total190105282
Total current liabilities1,5941,1081,459
Total long term debt386256196
Total debt1,116620533
Deferred income tax101483.63
Minority interest0.00----
Other liabilities, total------
Total liabilities2,0811,4121,659
SHAREHOLDERS EQUITY
Common stock487487162
Additional paid-in capital8080410
Retained earnings (accumulated deficit)1,7991,4161,177
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total21208.23
Total equity2,3872,0031,757
Total liabilities & shareholders' equity4,4683,4163,416
Total common shares outstanding494916
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.